Clinical Trial Update: Study of Oral Dasatinib in Subjects With Myelodysplastic Syndrome (MDS) and Excess Marrow Blasts [NA]

View source ↗

Summary

A completed study evaluated oral dasatinib in patients with myelodysplastic syndromes with excess marrow blasts. Results were posted in 2012.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myelodysplastic Syndromes

Drugs mentioned

• Sprycel (dasatinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Myelodysplastic Syndromes | NA | Status: COMPLETED | Results posted: 2012-06-25